

## Trial Summary

- In this clinical trial, participants will receive either satralizumab with or without background therapy, or placebo with or without background therapy. *Background therapy is the treatment participants have been taking regularly to prevent MOGAD attacks (relapses).*
- This is a double-blind study. *Double-blind means that neither the patient nor the study doctor can choose or know which group the patient is in.*
- All participants will be randomly assigned (like flipping a coin) to either receive satralizumab (the investigational medicine) or placebo (looks like the investigational medicine but is not a real medicine) alone or in addition to their current MOGAD medication

The main goal of the study is to compare the effects, good or bad, of **satralizumab** and placebo with or without background therapy in patients with MOGAD